Tezspire

Drug

Also known as: Tezspire, TEZSPIRE

Related News

Aclaris Therapeutics Details TSLP/ITK Pipeline with Multiple Clinical Readouts Expected in Late 2026

Apr 28, 2026

Aclaris Therapeutics outlined its TSLP antibody and ITK kinase pipeline at the Guggenheim Biotech Summit, with Phase II AD results for bosakitug due in late 2026 and Phase 1b studies for bispecific ATI-052 underway. The company will also announce Phase 1a results for ATI-052 and lead indication selection for ATI-2138 on April 28, 2026.

Barclays initiates Amgen coverage with Equal Weight rating and $185 price target

Apr 12, 2026

Barclays initiated Amgen with an Equal Weight rating and a $185 price target as debate over the Phase 3 MARITIME trial continued. Amgen said 2025 revenue and earnings per share rose by double digits.

Amgen Stock Rises on Pipeline Expansion and Strong Q4 Results

Mar 03, 2026

Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.